Literature DB >> 29659211

Ketamine for Depression, 6: Effects on Suicidal Ideation and Possible Use as Crisis Intervention in Patients at Suicide Risk.

Chittaranjan Andrade1.   

Abstract

A growing body of literature suggests that ketamine, administered in subanesthetic doses, has early-onset antidepressant action in patients with severe and even treatment-refractory depression. Many case reports, open-label studies, and randomized controlled trials (RCTs) suggest that ketamine may have dramatic antisuicidal effects, as well. This article examines the benefits of ketamine in patients with suicidal ideation with particular focus on the findings of recent RCTs and meta-analyses. Important findings are that a single dose of ketamine is associated with antisuicidal benefits that emerge within an hour of administration and persist for up to a week. The benefits are seen in patients with mild as well as clinically significant suicidal ideation. The benefits are observed in midazolam- as well as saline-controlled trials. Effect sizes are medium to large. The improvement in suicidal ideation is only partly explained by improvement in depression severity. It is concluded that there is consistent evidence that a single dose of ketamine has dramatic antisuicidal action that emerges almost immediately after dosing and persists for at least a week. The short- and intermediate-term safety and efficacy of ketamine as a crisis intervention treatment for suicidal patients merit study. Areas that need research are outlined. © Copyright 2018 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29659211     DOI: 10.4088/JCP.18f12242

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  6 in total

Review 1.  Suicide Has Many Faces, So Does Ketamine: a Narrative Review on Ketamine's Antisuicidal Actions.

Authors:  Aiste Lengvenyte; Emilie Olié; Philippe Courtet
Journal:  Curr Psychiatry Rep       Date:  2019-12-03       Impact factor: 5.285

2.  Infusing hope into the treatment of suicidality: A review of ketamine's effects on suicidality.

Authors:  Manivel Rengasamy; Kimberly Hsiung; Rebecca B Price
Journal:  Curr Behav Neurosci Rep       Date:  2019-12-02

Review 3.  How Does COVID-19 Affect the Neurobiology of Suicide?

Authors:  I Conejero; B Nobile; E Olié; Ph Courtet
Journal:  Curr Psychiatry Rep       Date:  2021-03-03       Impact factor: 5.285

Review 4.  Genetic variables of the glutamatergic system associated with treatment-resistant depression: A review of the literature.

Authors:  Estela Saez; Leire Erkoreka; Teresa Moreno-Calle; Belen Berjano; Ana Gonzalez-Pinto; Nieves Basterreche; Aurora Arrue
Journal:  World J Psychiatry       Date:  2022-07-19

Review 5.  Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors.

Authors:  Domenico De Berardis; Michele Fornaro; Alessandro Valchera; Marilde Cavuto; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Annastasia Fiengo; Antonio Ventriglio; Kim Yong-Ku; Giovanni Martinotti; Massimo Di Giannantonio; Carmine Tomasetti
Journal:  Int J Mol Sci       Date:  2018-09-23       Impact factor: 5.923

6.  Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial.

Authors:  Sanne Y Smith-Apeldoorn; Jolien K E Veraart; Jeanine Kamphuis; Antoinette D I van Asselt; Daan J Touw; Marije Aan Het Rot; Robert A Schoevers
Journal:  BMC Psychiatry       Date:  2019-11-29       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.